Table 2.
KIF20A worked as a tumor-associated antigen.
| Tumor | Clinical trial | Peptides combination therapy | Results | Reference |
|---|---|---|---|---|
| Biliary tract cancer | phase I | cell division cycle associated 1 (CDCA1), cadherin 3 (CDH3) | Peptide vaccines were well tolerated, and no serious adverse events were observed after vaccination. Peptide specific T cell immune response was also observed in all patients. | [68] |
| Biliary tract cancer | ND | VEGFR1, VEGFR2 | Four out of six patients exhibited vaccine-specific T-cell responses. Vaccine-specific T cell responses contributed significantly to overall survival. | [69] |
| Gastric cancer | ND | DEPDC1, URLC10, FoxM1, and VEGFR1 | Patients who showed T cell responses specific to antigen peptides had a tendency towards better survival. The Patients with local skin reactions had significantly better OS | [73] |
| Gastric cancer | ND | DEPDC1, URLC10, FOXM1, and VEGFR1, combined with S-1 | No adverse events of grade 3 or higher were observed. | [74] |
| Gliomas | ND | LY6K, DEPDC1, FOXM1, VEGFR1 and VEGFR2 | The treatment was well tolerated, induced immunoreactivity, and contributed to overall survival. | [76] |
| Head-and-neck malignant tumor | ND | ND | KIF20A specific Th1 cell response was detected after short-term stimulation of PBMC. | [67] |
| Pancreatic cancer | ND | ND | KIF20A peptide induced CTL with peptide specific cytotoxicity. | [63] |
| Pancreatic cancer | phase I/II | ND | OS time of the patients was significantly prolonged. | [65] |
| Pancreatic cancer | phase I | ND | Patients was well tolerated. No serious adverse events were observed. Peptide specific T cell responses were detected. | [66] |
| Pancreatic cancer | phase I | gemcitabine | No serious adverse reactions related to KIF20A peptide were observed. Of the 9 patients who completed at least one course of treatment, 4 of the them were induced to produce IFN-g cells, and 4 were stable. | [70] |
| Pancreatic cancer | Phase II | VEGFR1 and VEGFR2 | Peptide-specific CTL induction for KIF20A or VEGFR1 showed a better prognosis. Patients who showed a strong injection site reaction had a better survival rate | [72] |
| Pancreatic cancer | Phase II | VEGFR1 and VEGFR2 combined with gemcitabine | Vaccine was well tolerated and induced KIF20A-specific CTL responses. All four patients who underwent R0 resection with KIF20A expression had no recurrence of pancreatic cancer with KIF20A-specific CTL responses. Vaccine contributed to overall survival. | [71] |
| Pediatric refractory solid tumors | ND | KOC1 and FOXM1 | Induce a sufficient number of peptide specific CTLs, contributed to free survival. | [75] |